| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 48,389 | 52,446 | ||
| Short-term investments | 940,604 | 943,565 | ||
| Prepaid expenses and other current assets | 9,093 | 9,542 | ||
| Total current assets | 998,086 | 1,005,553 | ||
| Restricted cash | 816 | 816 | ||
| Total property and equipment | 10,813 | - | ||
| Less accumulated depreciation | 6,499 | - | ||
| Property and equipment, net | 4,314 | 4,688 | ||
| Operating lease right-of-use assets | 18,923 | 18,462 | ||
| Other long-term assets | 2,627 | 2,693 | ||
| Total assets | 1,024,766 | 1,032,212 | ||
| Accounts payable | 3,395 | 3,477 | ||
| Accrued expenses | 22,156 | 16,029 | ||
| Current portion of operating lease liabilities | 2,280 | 1,873 | ||
| Total current liabilities | 27,831 | 21,379 | ||
| Operating lease liabilities, net of current portion | 20,380 | 20,317 | ||
| Total liabilities | 48,211 | 41,696 | ||
| Common stock, 0.001 par value authorized shares - 200,000,000 at september 30, 2025 and december 31, 2024 issued and outstanding shares - 60,123,602 and 59,064,606 at september 30, 2025 and december 31, 2024, respectively | 60 | 59 | ||
| Additional paid-in capital | 1,291,369 | 1,281,833 | ||
| Accumulated other comprehensive income | 4,562 | 3,747 | ||
| Accumulated deficit | -319,436 | -295,123 | ||
| Total stockholders' equity | 976,555 | 990,516 | ||
| Total liabilities and stockholders' equity | 1,024,766 | 1,032,212 | ||
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)